Syndax Pharmaceuticals - 25 Mg Revuforj Tablets Expected to Be Commercially Available in Late Q1 or Early Q2 of 2025Nov 15 (Reuters) - Syndax Pharmaceuticals Inc Sndx.o:
11月15日（路透社）— Syndax 製藥公司 sndx.o:
Syndax Announces FDA Approval of Revuforj® (Revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients With Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
Syndax Pharmaceuticals Inc - Revuforj 110 and 160 Mg Tablets Expected to Be Available for Order in U.S. in November
Syndax Pharmaceuticals - 25 Mg Revuforj Tablets Expected to Be Commercially Available in Late Q1 or Early Q2 of 2025
Syndax Pharmaceuticals: Before Commercial Availability of 25 Mg Tablets, Oral Solution of Revumenib to Be Available Through Expanded Access Program
Syndax宣佈美國食品藥品管理局批准Revuforj®（Revumenib），這是第一種也是唯一一種使用Kmt2a易位治療復發或難治性急性白血病的成人和兒童患者的腦膜炎抑制劑
Syndax Pharmicals Inc-Revuforj 110 和 160 毫克片劑預計將於 11 月在美國上市
Syndax 製藥——25 毫克 Revuforj 片劑預計將於 2025 年第一季度末或第二季度初上市
Syndax Pharmicals：在25毫克片劑商業上市之前，Revumenib的口服溶液將通過擴大准入計劃上市
Source Text: Id:Npn3Nsdvka
源文本： ID: npn3nsdvka
Further Company Coverage: Sndx.o
更多公司報道： sndx.o
((Reuters.briefs@Thomsonreuters.com;))
((Reuters.briefs@Thomsonreuters.com;))
